Ojobumijo Agbaji, MD
Pulmonary Disease · Laconia, NHNPI 1689195042
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AstraZeneca at 30.0% of the total. Reporting peaked in 2023 at $92 and has fallen 53.5% since, to $43 in 2025. That places this record below the midpoint for pulmonary disease clinicians in NH, where the typical reported total is $278.
Across 14 payments — averaging $24.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$103
- GSK$63
- Regeneron Healthcare Solutions, Inc.$46
- Boston Scientific$44
- Grifols USA, LLC$30
- Vertex$23
- plus $33 from 2 others
What the payments were for
- Food & beverage$342100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 4 | $103 |
| GSK | 3 | $63 |
| Regeneron Healthcare Solutions, Inc. | 1 | $46 |
| Boston Scientific | 2 | $44 |
| Grifols USA, LLC | 1 | $30 |
| Vertex | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Insmed, Inc. | 1 | $16 |
How this compares
$342 in reported general payments places this provider in the 50th percentile of 78 pulmonary disease providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 196 | $142,946 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 43 | $19,343 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 31 | $15,815 |
| Spiriva RespimatTiotropium Bromide | 26 | $13,930 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $10,798 |
| Incruse ElliptaUmeclidinium Bromide | 15 | $5,991 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $4,713 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $4,647 |
| Varenicline Tartrate | 12 | $3,131 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $2,533 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 13 | $2,406 |
| Wixela InhubFluticasone Propion/Salmeterol | 20 | $1,957 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 73 | $1,461 |
| Pantoprazole Sodium | 59 | $677 |
| Fluticasone Propionate | 35 | $421 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $63 | $168,280254 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $103 | $15,51133 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 78 pulmonary disease providers in New Hampshire.
Other pulmonary disease in Laconia
- Kamen RangelovLaconia$669
- Fady Abou RizkLaconia$61
- Donald MahlerLebanon$411K
- Bianca MonteiroDover$43K
- Jeffrey StewartLebanon$30K
- Erik SwensonLebanon$29K
- Elliot BackerLebanon$24K
- H ParkerLebanon$13K
- Christopher DaigleNashua$12K
- Danilo AblanPortsmouth$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.